Stockreport

Erasca stock sinks 50% after patient death in drug trial [Yahoo! Finance]

Erasca, Inc.  (ERAS) 
PDF About a month into treatment with ERAS-0015, Erasca's experimental pan-RAS molecular glue, the 66-year-old man — who had metastatic pancreatic cancer — was hospitalized [Read more]